ArticlePsychopharmacology2016
Orexin A-induced enhancement of attentional processing in rats: role of basal forebrain neurons.
Article in Psychopharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Sex differences in interactions between the muscarinic-1 and orexin-1 receptors on cognitive flexibility in rats.Brain research · 2026Article
- Implication of orexin transmission in chronic stress, hyperarousal, and neuroplasticity deficits: a mechanistic framework for depression and anxiety.Frontiers in psychiatry · 2026Review
- The orexin/hypocretin system in dementia-related neurological disorders: a double-edged sword in cognitive impairment.Psychopharmacology · 2025Review
- Orexin/Hypocretin Modulates Neuroinflammatory Response to LPS in a Sex and Brain-Region Specific Manner in Young Rats.Journal of neurochemistry · 2025Article
- Dual orexin/hypocretin receptor antagonism attenuates NMDA receptor hypofunction-induced attentional impairments in a rat model of schizophrenia.Behavioural brain research · 2023Article
- Dual orexin/hypocretin receptor antagonism attenuates attentional impairments in an NMDA receptor hypofunction model of schizophrenia.bioRxiv : the preprint server for biology · 2023Article
- Intranasal insulin and orexins to treat age-related cognitive decline.Physiology & behavior · 2021Review
- Orexinergic System in Neurodegenerative Diseases.Frontiers in aging neuroscience · 2021Review
- Hypocretin (Orexin) Replacement Therapies.Medicine in drug discovery · 2020Article
- Intranasal administration of orexin peptides: Mechanisms and therapeutic potential for age-related cognitive dysfunction.Brain research · 2020Review
- Orexin/hypocretin and dysregulated eating: Promotion of foraging behavior.Brain research · 2020Review
- Decreased serum orexin A levels in drug-naive children with attention deficit and hyperactivity disorder.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019Article
- Effects of Intranasal Orexin-A (Hypocretin-1) Administration on Neuronal Activation, Neurochemistry, and Attention in Aged Rats.Frontiers in aging neuroscience · 2019Article
- Nucleus Accumbens Shell Orexin-1 Receptors Are Critical Mediators of Binge Intake in Excessive-Drinking Individuals.Frontiers in neuroscience · 2019Article
- The hypocretin/orexin system as a target for excessive motivation in alcohol use disorders.Psychopharmacology · 2018Review
- Increased acetylcholine and glutamate efflux in the prefrontal cortex following intranasal orexin-A (hypocretin-1).Journal of neurochemistry · 2018Article
- Activation of orexin/hypocretin neurons is associated with individual differences in cued fear extinction.Physiology & behavior · 2017Article
- Hypocretinergic and cholinergic contributions to sleep-wake disturbances in a mouse model of traumatic brain injury.Neurobiology of sleep and circadian rhythms · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
rationaleOrexins are neuropeptides released in multiple brain regions from neurons that originate within the lateral hypothalamus and contiguous perfornical area. The basal forebrain, a structure implicated in attentional processing, receives orexinergic inputs. Our previous work demonstrated that administration of an orexin-1 receptor antagonist, SB-334867, systemically or via infusion directly into the basal forebrain, can disrupt performance in a task that places explicit demands on attentional processing.
objectivesGiven that the orexin-1 receptor binds orexin A with high affinity, we tested whether orexin A could enhance attention in rats.
methodsAttentional performance was assessed using a task that required discrimination of variable duration visual signals from trials when no signal was presented. We also tested whether infusions of orexin A into the lateral ventricle could attenuate deficits following lesions of medial prefrontal cortical cholinergic projections that arise from the basal forebrain.
resultsInfusions of orexin A into the basal forebrain attenuated distracter-induced decreases in attentional performance. Orexin A attenuated deficits in lesioned animals when a visual distracter was presented.
conclusionThe present results support the view that orexin A can enhance attentional performance via actions in the basal forebrain and may be beneficial for some conditions characterized by attentional dysfunction due to disruption of cortical cholinergic inputs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.